Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 12, 2024Open Access

Optimal antiplatelet therapy for acute coronary syndrome patients with high risk for both ischemia and bleeding

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYachao LiHunan UniversityMLMengjie LeiHebei Medical UniversityJWJingyao WangNorth China University of Science and Technology

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e651bbb6db6435875e1cd5https://doi.org/10.21203/rs.3.rs-4441754/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk2021 · 588 citations
  2. 2Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study2017 · 414 citations
  3. 3Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention2016 · 930 citations
  4. 4Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents2016 · 558 citations
  5. 52020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region2021 · 26 citations